691361-76-9

Upstream product

• 96-72-0 2-chloro-5-nitrobenzenesulfonamide 
• 54734-85-9 2-amino-5-nitrobenzenesulfonamide 
• 1000312-84-4 N-(1,1,3-trioxo-1,2,3,4-tetrahydro-1λ⁶-benzo[1,2,4]thiadiazin-7-yl)methanesulfonamide 
• 124-63-0 methanesulfonyl chloride 
• 3306-62-5 2-AMINOBENZENESULFONAMIDE 
• 1694-92-4 2-Nitrobenzenesulfonyl chloride 
• 4533-95-3 5-nitro-2-chlorobenzenesulfonyl chloride 
• 1000313-17-6 2-benzylamino-5-nitro-benzenesulfonamide 
• 96-75-3 2-amino-5-nitro-benzenesulfonic acid 
• 5455-59-4 2-Nitrobenzenesulfonamide 
• 13338-00-6 2H-1,2,4-benzothiadiazin-3(4H)-one 1,1-dioxide 
• 1071519-76-0 2,5-diamino-benzenesulfonamide methanesulfonate 
• 20628-33-5 2-Amino-5-nitro-benzolsulfonylchlorid 
• 30693-53-9 2-amino-5-nitrobenzenesulfonic acid sodium salt 

Downstream Products

• 1000313-18-7 N-(4-(methanesulfonylamino)-2-sulfamoyl-phenyl)malonamic acid ethyl ester 
• 1000313-19-8 N-(4-methanesulfonylamino-2-sulfamoylphenyl)malonamic acid methyl ester 
• 1056901-19-9 N-{3-[5-(S)-(4-fluoro-benzyl)-8-hydroxy-5-methyl-6-oxo-5,6-dihydro-indolizin-7-yl]-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide 
• 1190951-73-5 C₂₄H₂₆N₄O₆S₂ 
• 1190951-75-7 C₂₅H₃₁N₃O₇S₂ 
• 1186307-60-7 C₂₂H₂₈N₄O₇S₂ 
• 1186307-52-7 N-[3-(4-benzyl-7-hydroxy-5-oxo-4,5-dihydro-pyrazolo[1,5-a]pyrimidin-6-yl)-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl]-methanesulfonamide 
• 1186307-53-8 N-{3-[4-(4-fluoro-benzyl)-7-hydroxy-5-oxo-4,5-dihydro-pyrazolo[1,5-a]pyrimidin-6-yl]-1,1-dioxo-1,4-dihydro-1lλ6-benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide 
• 1186307-54-9 N-(3-{4-[2-(4-fluoro-phenyl)-ethyl]-7-hydroxy-5-oxo-4,5-dihydro-pyrazolo[1,5-a]pyrimidin-6-yl}-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl)-methanesulfonamide 
• 1186309-24-9 C₂₄H₁₉FN₄O₆S₂ 
• 1370714-06-9 N-[3-(1-benzyl-1H-indol-3-yl)-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methansulfonamide 
• 1071519-62-4 N-{3-[(1R,2S,7R,8S)-3-(4-fluorobenzyl)-6-hydroxy-4-oxo-3-azatricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl}methanesulfonamide L-lysine salt 
• 1071519-66-8 N-{3-[(1R,2S,7R,8S)-3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-tricyclo[6.2.1.0(2,7)]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl}methanesulfonamide sodium salt 
• 1071519-68-0 N-{3-[(1R,2S,7R,8S)-3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-tricyclo[6.2.1.0(2,7)]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl}methanesulfonamide potassium salt 

Relevant academic research and scientific papers

FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY

A compound of formula (I): which inhibits the activity of one or more KATs of the MYST family, i.e., TIP60, KAT6B, MOZ, HBO1 and MOF.

Integrated structure-based activity prediction model of benzothiadiazines on various genotypes of HCV NS5b polymerase (1a, 1b and 4) and its application in the discovery of new derivatives

This work presents the first structure-based activity prediction model for benzothiadiazines against various genotypes of HCV NS5b polymerase (1a, 1b and 4).The model is a comprehensive workflow of structure-based field template followed by guided docking. The field template was used as a pre-filter and a tool to provide hits in good orientation and position. It was created based on detailed molecular interaction field analysis which includes Topomer CoMFA, grid independent analysis and Superstar. On the other hand, Guided docking was used as a refinement and assessment tool. It was actively directed by two scores: Moldock score as an interaction descriptor (r2 = 0.65) and a template similarity score as a measure for accurate binding-mode compliance. The docking template was based on energy-based pharmacophore analysis. The whole procedure was formulated and tweaked for both screening (ROC of AUC = 0.91) and activity prediction (r2 of 0.8) for the genotype 1a. In order to widen the model scope, linear interaction energy was used as a tool for predicting activities of other genotypes based on the docked ligand poses while mutation binding energy was used to investigate the effect of each amino acid mutation in genotype 4. The model was applied for structure-based fragment hopping by screening a library designed by reaction enumeration. A top scoring hit was used to generate a focused library such that it has lower TPSA than the original class ligands and thus better pharmacokinetic properties. After that, experimental validation was carried out by the synthesis of this library and its biological evaluation which yielded compounds that exhibit EC50 ranging from 1.86 to 23 μM.

A METHOD OF INHIBITING HEPATITIS C VIRUS BY COMBINATION OF A 5,6-DIHYDRO-1H-PYRIDIN-2-ONE AND ONE OR MORE ADDITIONAL ANTIVIRAL COMPOUNDS

The invention is directed to a method of treating infections by hepatitis C virus by administering N-{3-[(1R,2S,7R,8S)-3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1 -dioxo-l,4-dihydro-lλ6- benzo[l,2,4]thiadiazin-7-yl} -methanesulfonamide and one or more additional antiviral compounds or pharmaceutical compositions containing such compounds.

PYRIDAZINONE COMPOUNDS

The invention is directed to pyridazinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.

Efficient large-scale synthesis of 2-amino-5- methanesulfonylaminobenzenesulfonamide

A novel synthesis of 2-amino-5-methanesulfonylaminobenzenesulfonamide is described. This preparation begins with readily available 4-nitroaniline and proceeds through five steps (isolations) in 41% overall yield. The described chemistry is conducted on a 50- to 100-g scale and does not require extractive workup procedures or chromatographic purifications. Copyright Taylor & Francis Group, LLC.

5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS

The invention is directed to 5,6-dihydro-lH-pyridin-2-one compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.

SATURATED FUSED [1,2-B] PYRIDAZINONE COMPOUNDS

The invention is directed to saturated fused [1,2-b]pyridazinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.

5,5-DISUBSTITUTED-INDOLIZINONE COMPOUNDS

The invention is directed to 5,5-disubstituted-indolizinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.

PYRIDAZINONE COMPOUNDS

The invention is directed to pyridazinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.